Mankind Pharma Limited

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the dispatch of the Notice of Postal Ballot and providing other requisite information pursuant to the provisions of Sections 108 and 110 of the Companies Act, 2013.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding Notice of Postal Ballot for appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director of the Company.

Mankind Pharma Limited

Mankind Pharma Limited has completed the realignment of security cover for its non-convertible debentures, resulting in the release of pledged shares of Bharat Serums and Vaccines Limited. The revised security cover is 1.26 times the outstanding NCDs as on date.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about the incorporation of a wholly owned subsidiary company in Netherlands, Mankind Pharma (Netherlands) B.V., as per the Listing Regulations.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director of the company, effective from August 10, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding the outcome of its Board Meeting held on August 10, 2026, where the Board appointed Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, subject to approval of the members of the Company.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about its participation in upcoming investor conferences, including Emkay Confluence, Equirus Annual India Conference, and Motilal Oswal 22nd Annual Global One-on-One Investor Conference.

Mankind Pharma Limited

Mankind Pharma Limited has submitted the Exchange a copy of the Scrutinizer's report of the 35th Annual General Meeting held on August 04, 2026, and informed the Exchange regarding voting results.

Mankind Pharma Limited

Mankind Pharma Limited held its 35th Annual General Meeting on August 4, 2026, through video conferencing, with 143 members in attendance. The meeting was presided over by Executive Chairman Ramesh Juneja, and the company's financials for the year 2025-26 were discussed.

Mankind Pharma Limited

Mankind Pharma Limited's Q1 FY27 earnings conference call transcript is available on their website, with key highlights including a 13% year-on-year revenue growth to INR4,031 crores, EBITDA of INR1,060 crores, and an EBITDA margin improvement of 250 bps to 26.3%. The company also reported a 12.7% growth in secondary sales as per IQVIA, driven by healthy volume growth of 4.7% and strong momentum in chronic and BSV specialty business.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about a copy of newspaper publication regarding unaudited financial results for the quarter ended June 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has made available the audio recording of its Q1FY27 investor conference call on its website.

Mankind Pharma Limited

Mankind Pharma Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with the company's board of directors approving the issuance of a corporate guarantee in favor of Bharat Serums and Vaccines Limited, a wholly-owned subsidiary. The company has also submitted a certificate from its joint statutory auditors under Regulation 54 of the SEBI (LODR) Regulations, 2015.

Mankind Pharma Limited

Mankind Pharma Limited has announced its Q1FY27 financial results, showing revenue growth of 12.9% YoY, EBITDA growth of 24.7% YoY, and PAT growth of 29.1% YoY. The company's domestic business (ex-CH) grew by 11.0% YoY, driven by double-digit growth in Mankind business and strong growth in BSV specialty business. The company has also launched 1 new product in Q1FY27, taking the total launched products to 49 in the US.

Mankind Pharma Limited

Mankind Pharma Limited has announced its Q1 FY27 financial results, showing a 12.9% YoY growth in revenue from operations, with domestic business (ex-CH) growing 11.0% YoY and exports business growing 29.0% YoY. The company has also reported a 16.5% YoY growth in gross profit and a 24.7% YoY growth in EBITDA.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about giving guarantees/indemnity/becoming a surety for a third party, and has also approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the issuance of corporate guarantee in favour of Bharat Serums and Vaccines Limited.

Mankind Pharma Limited

Mankind Pharma Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and has also approved the issuance of a corporate guarantee in favor of Bharat Serums and Vaccines Limited. The company has also provided a certificate from its joint statutory auditors for the quarter ended June 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has completed the sale of 100% stake in Broadway Hospitality Services Private Limited for ₹ 49 Crore, as per the Share Purchase Agreement executed on July 27, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about a scheduled investor conference call to discuss Q1FY27 business performance and results on July 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about the acquisition of 100% stake in Broadway Hospitality Services Private Limited and the incorporation of a wholly owned subsidiary company in Netherlands to act as a Special Purpose Vehicle for holding investments in R&D assets and business development activities focused on treatment of niche therapies.